Recruiting
Phase 3

Vorasidenib & Temozolomide

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT07215910

Conditions

Astrocytoma, IDH-Mutant, Grade 3

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Intensity-Modulated Radiation Therapy

Volume Modulated Arc Therapy

Pencil Beam Scanning

Intensity-Modulated Proton Therapy

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-20. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2026-06-16.